Huons lidocaine recall: 12 kit notices, 7 kit makers, and a two-month lag

On March 25, 2026, Huons Co., Ltd. agreed to recall every unexpired drug its plant in Jecheon, South Korea had made for the U.S. market. FDA had recommended exactly that on a call the day before. The trigger was an inspection that found, among other things, a microbiology team leader telling staff to throw away bioburden plates with significant growth.

Most of those drugs did not reach hospitals in a Huons carton. They arrived as one glass ampule inside somebody else's procedure tray, such as a B. Braun spinal anesthesia kit or an Argon bone marrow tray. Between June 3 and September 10, FDA posted 12 device notices from seven kit makers that found Huons ampules in their bills of materials. Several of them got the ampules secondhand, under another company's label or inside another kit maker's component.

This is an ingredient recall cascade on the device side, and it is harder to see than the food version: the recalled ingredient is a drug, and the product carrying it is a device.

What FDA found at the Jecheon plant

FDA inspected the facility November 12 to 21, 2025. According to the warning letter (MARCS-CMS 724650, dated June 15, posted June 23):

• A study run on a compounding tank failed endotoxin limits and the next run showed significant bioburden. The team leader "had instructed staff to discard the bioburden plates with significant growth and had manipulated camera timestamps to create backdated documentation." The endotoxin failure was never documented or investigated.
• Investigators found 1,897 blank, uncontrolled CGMP forms in the microbiology labs.
• The microbiology team leader "admitted to using a knife to remove completed pages from the logbook," and the pages were replaced with fabricated ones.
• Smoke studies showed turbulent airflow on an ampoule filling line, with an operator's head and upper body fully inside the Grade A area during interventions.

For anyone downstream, the most important sentence is Huons' own, quoted back in the letter: because of the data problems, "it may be premature to draw conclusions about product impact based on the sterility assurance data from sterility testing results and media fill results from the previous three years." Three years of sterility records could not be used to clear the product, which makes it hard to see how a narrower recall could have been justified.

FDA placed the firm on Import Alert 66-40 on April 3, 2026, and Huons committed to suspend production for the U.S. market.

The drug recall itself was Class II

Huons' recall, initiated April 2, sits in FDA's Enforcement Report as four Class II entries (D-0529-2026 through D-0532-2026), all for "Lack of Assurance of Sterility," all lots within expiry, nationwide:

Product	Quantity listed
Lidocaine HCl Injection 1%, 5 mL	33,599,925 ampules and 23,658,125 vials
0.9% Sodium Chloride Injection, 10 mL ampules, made for Spectra Medical Devices	7,120,750 ampules
Bupivacaine HCl 0.75% in 8.25% Dextrose Injection	3,260,170 ampules
Lidocaine HCl Injection 2%, 5 mL	not stated

The labels went out under several names. Besides Huons' own NDCs (73293), the entries list Brookfield Pharmaceuticals (71351), McKesson's Sky Packaging (63739-170), Precision Dose (68094-081), Novagenix Labs (84769) and Spectra (65282-1510). Two of the four entries spell the manufacturer "Houns." A recall check that matches on the exact manufacturer name would miss the saline and the bupivacaine.

Seven kit makers, three tiers deep

Tier one: kit makers holding Huons ampules. BD went first, with a June 3 notice for spinal trays containing bupivacaine. Medline followed on June 12 for spinal kits, and again on August 3 for kits with lidocaine. Arrow International, a Teleflex subsidiary, posted July 16 for kits and sets containing all three drugs. B. Braun posted the same day for its Pencan and Spinocan spinal kits.

Tier two: kit makers that got Huons ampules through Spectra. Argon Medical's July 30 notice covers bone marrow trays, transvenous pacing trays, an arterial line kit and a general biopsy tray, all containing Spectra pain management kits with Huons lidocaine. Medical Action Industries (early alert August 21, classified notice September 10) and AVID Medical (early alert September 2) pulled Huons saline flush ampules recalled by Spectra from epidural, nerve block and biopsy trays. BD's August 18 early alert covers saline ampules "recalled by Elevaris Medical Devices." Spectra's own saline recall (Z-2873-2026) was classified Class I in August and says the ampules went to "medical device kit packers in six (6) states."

Tier three: kits inside kits. Medline's August 12 notice covers hip and knee kits that contain ICU Medical pain management kits with Huons bupivacaine. Its August 20 notice covers hip, knee and C-section kits built with B. Braun components that contain Huons bupivacaine. In both, the Huons ampule reached Medline already packed inside another company's kit.

B. Braun reported 35 serious injuries

B. Braun is the outlier. Its notice reports 35 serious injuries and no deaths as of April 24. Its three Enforcement Report entries list 702,830 kits, and it is the only one of the seven that told customers to remove and return product. Everyone else told users to discard the ampule and use the rest of the kit. Argon reported 2 serious injuries as of June 1. The other notices report none, and none reports a death.

Neither the notices nor the Enforcement Report says what the 35 injuries were. Medline's entries cite "reported efficacy complaints" and BD's notice cites "limited reports of drug ineffectiveness." B. Braun's notice lists emergency conversion to general anesthesia as a risk of compromised bupivacaine. Our reading: ineffective spinal anesthesia is a plausible explanation for the B. Braun count, but nothing public says so.

Classification split the signal

The same saline ampule is Class II as a Huons drug recall and Class I as a Spectra device recall. All nine classified kit notices FDA posted carry the "most serious type" label. In the Enforcement Report, we count at least 80 device entries through September 15 that tie kits or flushes to Huons components: 65 Class I and 15 Class II (Medline lidocaine kits such as suture trays and arterial line trays). FDA does not explain the split in these records. The practical point is simpler. A hospital that watched only Class I recalls would have missed the drug recall itself. A hospital that watched only drug recalls would have missed every kit.

FDA's notices ran about two months behind the customer letters

Every FDA kit notice dates the kit maker's letter to customers. For the eight classified recall notices that give a specific date (Arrow's says only "April 2026"), FDA's public page went up 37 to 89 days after the letter, a median of about two months. B. Braun told customers on April 26. FDA's page went up July 16, 81 days later. The three early alerts in this thread, all posted from August 18 on, came 8 to 29 days after the letter.

Our reading: for kit recalls, the customer letter is the alert and the FDA page is the public record that follows. If your recall process starts when FDA posts, you were roughly two months behind on most of this thread.

What to do this week

1. Run every drug component in your bills of materials by NDC and by manufacturer under every label name. For this recall that means the six labeler codes above, and "Houns" as well as "Huons."

2. Ask each component supplier, including any kit maker you buy subassemblies from, to confirm in writing whether its components contain a drug from a firm on Import Alert 66-40. Medline's two second-order notices show the subassembly is where this hides.

3. Write the "discard the ampule, keep the kit" over-label path into your recall SOP now. Six of the seven kit makers used it.

4. Route kit vendors' recall letters to pharmacy as well as materials management. The recalled component is a drug.

5. Stock replacement lidocaine, bupivacaine and saline for the procedure areas that use these trays. Several notices tell clinicians to secure an alternative before entering the procedure room.

6. Don't filter on Class I alone, and don't wait for FDA's page to act on a vendor letter.

If you don't use kits with drug components: no action is needed on this recall.

The thread is still open. BD's and AVID's early alerts have not yet been classified, and Huons' recall covers every in-date lot. Expect more notices.

Sources

• FDA Warning Letter to Huons Co., Ltd., MARCS-CMS 724650 / 320-26-95, June 15, 2026
• FDA Enforcement Report: Huons drug recalls D-0529-2026 to D-0532-2026; Spectra Medical Devices Z-2873-2026; kit entries from Arrow, BD, B. Braun, Medline and Argon
• FDA Medical Device Recalls and Early Alerts: B. Braun, Argon, Medline, B. Braun components, BD early alert, and eight related notices June 3 to September 10, 2026

Policy Canary tracks every FDA action, warning letters, recalls, guidance, and rules, against the specific products you make, by name and by ingredient. See what we would flag for your products.